This inventor holds 2 USPTO granted patents. Top assignee: Acerta Pharma B.v.. Active years: 2020-2021.
Company Filing History:
Years Active: 2020-2021
Title: Edwin De Zwart: Innovator in Pharmaceutical Chemistry
Introduction
Edwin De Zwart is a notable inventor based in Dreumel, Netherlands. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative compounds for therapeutic use. With a total of 2 patents to his name, his work focuses on addressing various medical disorders.
Latest Patents
One of Edwin De Zwart's latest patents involves imidazopyrazine inhibitors of Bruton's tyrosine kinase (BTK). This invention relates to a BTK inhibitor or a pharmaceutically acceptable salt, cocrystal, ester, prodrug, solvate, hydrate, or derivative thereof. The patent also covers pharmaceutical compositions comprising these compounds and their therapeutic applications. Specifically, the invention aims to treat hyperproliferative disorders, inflammatory disorders, immune disorders, and autoimmune disorders through the use of imidazopyrazine compounds and their pharmaceutical compositions.
Career Highlights
Edwin De Zwart is currently associated with Acerta Pharma B.V., where he continues to advance his research and development efforts. His work has been instrumental in creating innovative solutions for complex medical challenges.
Collaborations
Edwin has collaborated with notable colleagues such as Tjeerd Barf and Saskia Verkaik, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Edwin De Zwart's contributions to pharmaceutical chemistry exemplify the impact of innovative thinking in addressing critical health issues. His patents reflect a commitment to advancing medical science and improving patient outcomes.